FMR LLC boosts disclosure: PHARMA COMPANY NV (NAMS) 8.77M shares reported
FMR LLC has filed an amendment to Schedule 13G, disclosing a beneficial ownership of 8,765,811 shares of PHARMA COMPANY NV (NAMS) common stock, which represents a 7.6% stake in the company. The filing indicates that FMR LLC holds sole dispositive power over these shares, with no shared voting power. This update is a routine disclosure by an institutional investor, typically made when ownership or administrative details change, and its material impact would depend on future trading activity or shifts in ownership percentage.
MAR 21·MarketBeat▼
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has received a "Moderate Buy" consensus rating from twelve brokerages, with an average 1-year price target of $48.00 despite recent weak quarterly results and significant insider selling. The company reported an EPS miss of ($0.63) versus ($0.40) expected and revenue of $0.03M against estimates of $0.92M, while insiders offloaded shares worth $48.45M in the last three months, though they still own 20.84% of the stock. Institutional investors have generally increased their holdings.
FEB 7·The Manila Times▲
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma announced the grant of inducement share options for 217,000 ordinary shares to four new non-executive hires. These grants, approved by the Compensation Committee, are an inducement for employment and comply with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $31.57 and will vest over four years, with 25% vesting after one year and the remainder in monthly installments.
